Video
Why PSMA imaging is unique from other prostate cancer imaging technologies
Author(s):
We've never had an imaging agent like this before,” says Leonard S. Marks, MD.
Video Player is loading.
In this video, Leonard S. Marks, MD, gives an overview of the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer. He details how this technology will affect the detection and treatment of patients with this disease and is hopeful of its real-world application in the future. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.
Related Videos
Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
PSMA PET and treatment intensification in mHSPC
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
Amar Kishan, MD, on implications of MIRAGE trial data
Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
Amar Kishan, MD, outlines the rationale for the MIRAGE trial
Michael Cookson, MD, on potential future applications of PSMA-PET
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
Michael Cookson, MD, on challenges with PSMA-PET imaging
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
Related Content
